Smith & Nephew, Advanced Tissue Sciences announce Dermagraft receives CMS pass-through code.
The companies say the pass-through payment code for Dermagraft (C 9201) covers Medicare patients with diabetic foot ulcers treated in a hospital out-patient setting. It will be effective January 1, 2002. The FDA cleared the PMA for Dermagraft in the treatment of foot ulcers for diabetics on September 28. Dermagraft is the first human-based cryopreserved, living dermal substitute approved by the lFDA.
Contact: Advanced Tissue Sciences - (619) 450-5730
|Printer friendly Cite/link Email Feedback|
|Comment:||Smith & Nephew, Advanced Tissue Sciences announce Dermagraft receives CMS pass-through code.|
|Article Type:||Brief Article|
|Date:||Dec 28, 2001|
|Previous Article:||Baxter receives FDA clearance to market new pediatric peritoneal dialysis system.|
|Next Article:||Cloned pigs with rejection gene eliminated raises hopes for breakthrough in xenotransplantation.|